Shuttle Competitors

Stocks . USA . 
Stock . Shuttle Pharmaceuticals
SHPH Stock  USD 1.08  0.03  2.86%   
Shuttle Pharmaceuticals competes with Akanda Corp, Heart Test, Universe Pharmaceuticals, Theriva Biologics, and Biovie; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Shuttle Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Shuttle Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Shuttle Pharmaceuticals Correlation with its peers.
For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.

Shuttle Pharmaceuticals vs Im Cannabis Correlation

Weak diversification

The correlation between Shuttle Pharmaceuticals and IMCC is 0.37 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Shuttle Pharmaceuticals and IMCC in the same portfolio, assuming nothing else is changed.

Moving against Shuttle Stock

  0.43CMB Cambium BioPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.051.0910.94
Details
Intrinsic
Valuation
LowRealHigh
0.051.0510.90
Details
Naive
Forecast
LowNextHigh
0.021.1511.00
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-7.751.131.57
Details

Shuttle Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Shuttle Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Shuttle and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Shuttle Pharmaceuticals does not affect the price movement of the other competitor.

High positive correlations

IMCC
+ 0.83
AKAN
BIVI
+ 0.81
AKAN
ISPC
+ 0.76
AKAN
MSPR
+ 0.74
BIVI
IMCC
+ 0.72
BIVI
IMCC
+ 0.71
BBLG
  

High negative correlations

BIVI
- 0.63
HSCS
MSPR
- 0.59
HSCS
HSCS
- 0.54
AKAN
IMCC
- 0.46
HSCS
ISPC
- 0.35
HSCS
BBLG
- 0.26
HSCS

Risk-Adjusted Indicators

There is a big difference between Shuttle Stock performing well and Shuttle Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Shuttle Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
AKAN  7.75 (2.26) 0.00  14.81  0.00 
 0.00 
 11.11 
(20.00)
 64.81 
HSCS  4.11 (0.09)(0.01) 0.03  4.92 
(5.06)
 11.07 
(7.86)
 21.61 
UPC  5.07 (0.32) 0.00 (0.17) 0.00 
 0.00 
 13.75 
(9.34)
 52.35 
TOVX  5.56 (0.54) 0.00 (0.07) 0.00 
 0.00 
 11.11 
(13.64)
 38.10 
BIVI  3.32 (0.08) 0.00  0.30  0.00 
 0.00 
 8.16 
(7.30)
 23.28 
ISPC  5.91 (0.67) 0.00 (0.14) 0.00 
 0.00 
 10.00 
(10.53)
 41.56 
RDHL  3.39 (0.38) 0.00 (0.16) 0.00 
 0.00 
 3.88 
(5.50)
 46.87 
MSPR  12.65 (1.42) 0.00 (1.89) 0.00 
 0.00 
 45.45 
(23.08)
 132.25 
BBLG  3.53 (0.36) 0.00  0.58  0.00 
 0.00 
 7.14 
(9.52)
 22.82 
IMCC  4.28 (0.65) 0.00 (1.39) 0.00 
 0.00 
 11.39 
(10.92)
 35.18 

Shuttle Pharmaceuticals Competitive Analysis

The better you understand Shuttle Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Shuttle Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Shuttle Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SHPH AKAN HSCS UPC TOVX BIVI ISPC RDHL MSPR BBLG
 2.86 
 1.08 
Shuttle
 2.17 
 0.90 
Akanda
 2.43 
 2.81 
Heart
 1.34 
 2.95 
Universe
 11.11 
 0.20 
Theriva
 0.79 
 1.25 
Biovie
 7.69 
 0.28 
ISpecimen
 3.03 
 0.96 
Redhill
 12.50 
 0.04 
MSP
 3.39 
 1.14 
Bone
Market Volatility
(90 Days Market Risk)
Out of control
Out of control
Unstable
Dangerous
Out of control
Unstable
Abnormally volatile
Very steady
Out of control
Moderately volatile
Market Performance
(90 Days Performance)
Weakest
Weakest
Soft
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Risky
Risky
High
Risky
Risky
Risky
Risky
Risky
Risky
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Strong Buy
Not Available
Not Available
Strong Buy
Not Available
Not Available
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
0.03
0.48
3.53
5.06
4.14
4.5
13.37
0.98
1.0
80.11
Net Asset
2.51 M
7.91 M
4.22 M
69.3 M
35.35 M
21.56 M
9.35 M
18.04 M
1.92 B
3.86 M
Profit Margin
N/A
-2.66
N/A
-0.21
N/A
N/A
N/A
-0.98
N/A
N/A
EBITDA
(7.78 M)
(3.03 M)
(8.14 M)
(2.92 M)
(19.29 M)
(16.98 M)
(12.73 M)
(7.59 M)
(652.46 M)
107.16 K
Current Valuation
424.68 K
(1.17 M)
8.93 M
(37.01 M)
(5.33 M)
(2.12 M)
10.21 M
4.74 M
890.54 M
(4 M)
Price To Book
1.26
0.54
3.11
0.0458
0.37
0.79
16.9
203.21
0.0163
0.34
Operating Margin
N/A
-4.44
-857.13
-0.0677
N/A
N/A
-26.55
-1.07
-232.75
N/A
Retained Earnings
(34.58 M)
(57.46 M)
(76.13 M)
(13.84 M)
(334.97 M)
(352.14 M)
(71.86 M)
(414.8 M)
(446.05 M)
(85.02 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
9 K
N/A
60.51 M
N/A
1.07 M
Beta
0.46
1.69
2.54
1.52
0.57
0.52
1.84
4.88
-2.9
0.41
Number Of Employees
9
7
15
216
20
13
24
35
78
2
Shares Outstanding
3.25 M
2.1 M
3.18 M
563.34 K
35.69 M
7.54 M
9.77 M
5.11 M
1.04 M
1.8 M
Cash Flow From Operations
(7.33 M)
(3.98 M)
(7.41 M)
(5.05 M)
(16.94 M)
(19.03 M)
(8.26 M)
(9.37 M)
(16.12 M)
(4.12 M)
Total Debt
1.17 M
352.81 K
2.99 M
9.26 M
1.56 M
349.89 K
312.17 K
356 K
794.66 M
377.71 K
Return On Equity
-271.76
-0.61
-2.2
-0.0723
-1.67
-0.95
-2.96
-17.09
-7.66
-0.8
Return On Asset
-3.23
-0.29
-0.75
-0.0266
-0.29
-0.5
-0.75
-0.25
-0.14
-0.49
Number Of Shares Shorted
619.06 K
63.29 K
41.62 K
11.68 K
7.59 M
194.76 K
314.31 K
62.68 K
473.36 K
45.32 K
Book Value Per Share
1.13
22.67
1.36
99.64
0.65
3.31
0.31
-2.45
-294.71
3.35
Current Liabilities
N/A
N/A
N/A
N/A
N/A
961 K
N/A
5.51 M
N/A
2.16 M
Total Asset
2.51 M
7.91 M
4.22 M
69.3 M
35.35 M
21.56 M
9.35 M
18.04 M
1.92 B
3.86 M
Debt To Equity
0.091
0.027
0.41
0.072
0.027
3.34
0.14
9.89
0.043
N/A
Short Ratio
0.09
0.03
1.08
0.47
1.83
1.38
0.12
0.05
0.04
1.17
Target Price
N/A
N/A
10.6
N/A
7.0
12.0
3.0
19000.0
3.0
22.25
Shares Owned By Institutions
6.44
2.27
6.22
5.1
3.67
3.19
1.3
9.76
5.03
2.85
Market Capitalization
3.42 M
1.93 M
8.93 M
1.62 M
6.99 M
11.23 M
2.35 M
4.91 M
732.89 K
2.05 M
Price To Earning
N/A
N/A
N/A
3.02
N/A
18.12
0.78
-3.67
N/A
-15.45
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
-0.09
N/A
N/A
N/A
Price To Sales
N/A
2.31
1030.2
0.0908
N/A
N/A
0.7
0.51
0.0582
N/A
Net Income
(9.14 M)
(4.1 M)
(8.77 M)
(3.67 M)
(25.65 M)
(17.54 M)
(12.5 M)
(8.27 M)
(1.56 B)
(4.11 M)
Earnings Per Share
-3.42
154.84
-6.56
-8.06
2.06
-12.12
-7.82
N/A
-2471.98
-2.4
Shares Owned By Insiders
1.9
N/A
5.12
0.61
2.07
3.36
0.6
N/A
28.86
0.03
Revenue
N/A
836.66 K
4.35 K
17.86 M
N/A
N/A
9.29 M
8.04 M
18.25 M
N/A
Working Capital
677.15 K
1.42 M
(1.53 M)
40.43 M
8.7 M
18.42 M
(2.18 M)
(10.31 M)
(1.25 B)
3.48 M
Cash And Equivalents
50.44 K
N/A
4.27 M
28.58 M
52.27 M
18.64 M
23.69 M
28.86 M
25.05 M
5.45 M
Cash Per Share
N/A
N/A
0.52
1.31
3.3
0.62
2.67
0.55
0.38
0.53
Gross Profit
N/A
208.38 K
5.02 K
6.3 M
N/A
N/A
722.54 K
6.16 M
4.63 M
N/A
Day Typical Price
1.07
0.91
2.83
2.95
0.2
1.26
0.27
0.99
0.044
1.15
Accumulation Distribution
3397.7
2333.12
0.0243
10.96
144749.0
0.0462
62163.0
40970.8
4419.38
0.0339
Market Facilitation Index
0.0
0.0
0.07
0.0
N/A
0.06
N/A
N/A
N/A
0.04
Daily Balance Of Power
0.3333
(0.33)
(1.00)
(4.00)
2.0
(0.17)
0.5
(0.25)
0.7143
(1.00)
Period Momentum Indicator
0.03
(0.02)
(0.07)
(0.04)
0.02
(0.01)
0.02
(0.03)
0.005
(0.04)
Rate Of Daily Change
1.03
0.98
0.98
0.99
1.11
0.99
1.08
0.97
1.13
0.97
Day Median Price
1.07
0.92
2.85
2.95
0.2
1.27
0.26
1.01
0.0435
1.16
Price Action Indicator
0.03
(0.03)
(0.07)
(0.01)
0.015
(0.03)
0.03
(0.07)
0.004
(0.04)
Relative Strength Index
41.04
31.89
51.35
41.75
45.94
47.4
43.92
34.63
37.78
33.54
Coefficient Of Variation
95168.53
(487.81)
13045.27
(4,086)
(3,776)
(4,293)
(2,069)
(2,657)
(1,576)
(1,109)
Mean Deviation
7.09
7.75
4.11
5.07
5.56
3.32
5.91
3.39
12.65
3.53
Jensen Alpha
0.1581
(2.26)
(0.09)
(0.32)
(0.54)
(0.08)
(0.67)
(0.38)
(1.42)
(0.36)
Total Risk Alpha
(1.26)
(3.70)
(0.69)
(1.20)
(1.21)
(0.70)
(1.40)
(0.99)
(4.05)
(1.05)
Sortino Ratio
(0.01)
N/A
(0.01)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Variance
112.01
N/A
27.94
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Standard Deviation
9.79
11.07
5.65
7.79
7.76
4.52
7.86
5.88
21.05
4.75
Kurtosis
1.64
3.49
1.5
4.62
1.23
2.12
2.0
24.22
7.31
0.322
Potential Upside
15.69
11.11
11.07
13.75
11.11
8.16
10.0
3.88
45.45
7.14
Treynor Ratio
(0.0002)
14.81
0.0277
(0.17)
(0.07)
0.2995
(0.14)
(0.16)
(1.89)
0.5822
Maximum Drawdown
55.61
64.81
21.61
52.35
38.1
23.28
41.56
46.87
132.25
22.82
Variance
95.81
122.6
31.92
60.63
60.19
20.46
61.83
34.53
443.19
22.59
Market Risk Adjusted Performance
0.0098
14.82
0.0377
(0.16)
(0.06)
0.3095
(0.13)
(0.15)
(1.88)
0.5922
Risk Adjusted Performance
0.01
(0.15)
0.0145
(0.01)
(0.01)
(0.01)
(0.03)
(0.02)
(0.04)
(0.06)
Skewness
0.0888
0.8715
0.1144
0.8969
0.4066
1.01
0.9755
4.01
1.59
0.0714
Semi Deviation
9.66
N/A
4.92
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Information Ratio
(0.01)
(0.21)
(0.01)
(0.04)
(0.04)
(0.05)
(0.06)
(0.06)
(0.07)
(0.11)
Value At Risk
(12.50)
(20.00)
(7.86)
(9.34)
(13.64)
(7.30)
(10.53)
(5.50)
(23.08)
(9.52)
Expected Short fall
(7.34)
N/A
(5.06)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Deviation
10.58
N/A
5.29
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Semi Variance
93.33
N/A
24.22
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Shuttle Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Shuttle Pharmaceuticals Competition

Shuttle Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Shuttle Pharmaceuticals in relation to its competition. Shuttle Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Shuttle Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Shuttle Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Shuttle Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Shuttle Pharmaceuticals position

In addition to having Shuttle Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Russia On Wall Street Thematic Idea Now

Russia On Wall Street
Russia On Wall Street Theme
Cross-sector and cross-instrument bundle of publicly traded Russian entities that are expected to be listed on USA exchanges or over the counter. The Russia On Wall Street theme has 23 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Russia On Wall Street Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Shuttle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Shuttle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Shuttle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Shuttle Pharmaceuticals Stock:
How To Invest In Shuttle
Details
Is Shuttle Stock a good investment?
Details
What is Shuttle Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Shuttle Pharmaceuticals Correlation with its peers.
For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is there potential for Biotechnology market expansion? Will Shuttle introduce new products? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Shuttle Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY